{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:28:48Z","timestamp":1789457328649,"version":"build-2803163510"},"reference-count":46,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>\n            Background\u2003Guideline-recommended dual antiplatelet therapy (DAPT; aspirin plus prasugrel\/ticagrelor) for 12 months in acute coronary syndrome (ACS) patients increases bleeding, with East Asians (EAs) exhibiting higher bleeding and lower ischemic risk, compared with non-East Asians (nEAs). We sought to compare DAPT \u201cde-escalation\u201d strategies in EA and nEA populations.<\/jats:p><jats:p>\n            Methods\u2003A systematic review and meta-analysis of randomized controlled trials assessing reduction of DAPT intensity or duration in ACS patients undergoing percutaneous coronary intervention, in EA and nEA, was performed using a random-effects model.<\/jats:p><jats:p>\n            Results\u2003Twenty-three trials assessed reduction of DAPT intensity (n\u2009=\u200912) or duration (n\u2009=\u200911). Overall, reduced DAPT intensity attenuated major bleeding (odds ratio [OR]: 0.78, 95% confidence interval [CI]: 0.65\u20130.94, p\u2009=\u20090.009), without impacting net adverse cardiovascular events (NACE) or major adverse cardiovascular events (MACE). In nEA, this increased MACE (OR: 1.20, 95% CI: 1.09\u20131.31, p\u2009&lt;\u20090.0001) without impacting NACE or bleeding; while in EA, it reduced major bleeding (OR: 0.71, 95% CI: 0.53\u20130.95, p\u2009=\u20090.02) without affecting NACE or MACE. Overall, abbreviation of DAPT duration reduced NACE (OR: 0.90, 95% CI: 0.82\u20130.99, p\u2009=\u20090.03) due to major bleeding (OR: 0.69, 95% CI: 0.53\u20130.99, p\u2009=\u20090.006), without impacting MACE. In nEA, this strategy did not impact NACE, MACE, or major bleeding; while in EA, it reduced major bleeding (OR: 0.60, 95% CI: 0.4\u20130.91, p\u2009=\u20090.02) without impacting NACE or MACE.<\/jats:p><jats:p>\n            Conclusion\u2003In EA, reduction of DAPT intensity or duration can minimize bleeding, without safety concerns. In nEA, reduction of DAPT intensity may incur an ischemic penalty, while DAPT abbreviation has no overall benefit.<\/jats:p>","DOI":"10.1055\/s-0043-57030","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T23:07:31Z","timestamp":1681859251000},"page":"773-792","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis"],"prefix":"10.1055","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1451","authenticated-orcid":false,"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom"},{"name":"Centre for Health Services and Clinical Research, Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visvesh","family":"Jeyalan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaella I. L.","family":"Markides","sequence":"additional","affiliation":[{"name":"University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridgeshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliano P.","family":"Navarese","sequence":"additional","affiliation":[{"name":"Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland"},{"name":"Department of Cardiology, Faculty of Medicine, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0403-3726","authenticated-orcid":false,"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[{"name":"CAU Thrombosis and Biomarker Center, Chung-Ang University, Gwangmyeong Hospital, Seoul, Republic of Korea"},{"name":"Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0811-7679","authenticated-orcid":false,"given":"Mohamed","family":"Farag","sequence":"additional","affiliation":[{"name":"Centre for Health Services and Clinical Research, Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom"},{"name":"Department of Cardiology, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"issue":"14","key":"ref1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"J-P Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"B Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"20","key":"ref4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"S D Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamacardio.2016.2049","article-title":"Updates on acute coronary syndrome: a review","volume":"1","author":"A Eisen","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/eurheartj\/ehp110","article-title":"Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial","volume":"30","author":"R Mehran","year":"2009","journal-title":"Eur Heart J"},{"issue":"21","key":"ref8","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the Academic Research Consortium high bleeding risk definition in contemporary PCI patients","volume":"75","author":"D Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"H K Kim","year":"2021","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4070\/kcj.2020.0098","article-title":"Ethnic differences in oral antithrombotic therapy","volume":"50","author":"H Cho","year":"2020","journal-title":"Korean Circ J"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"S A Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"G N Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.scib.2018.12.020","article-title":"2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"64","author":"Y Huo","year":"2019","journal-title":"Sci Bull (Beijing)"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacasi.2021.12.005","article-title":"Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations","volume":"2","author":"O Kwon","year":"2022","journal-title":"JACC Asia"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"J PT Higgins","year":"2011","journal-title":"BMJ"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"S Saito","year":"2014","journal-title":"Circ J"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome \u2013 randomized, double-blind, phase III PHILO study","volume":"79","author":"S Goto","year":"2015","journal-title":"Circ J"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/FJC.0000000000000390","article-title":"Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"68","author":"X Tang","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2147\/TCRM.S108965","article-title":"Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome","volume":"12","author":"H Wang","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"23","key":"ref20","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"D W Park","year":"2019","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"C J Kim","year":"2021","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"H S Kim","year":"2020","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"M Gimbel","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"ref24","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","article-title":"Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization","volume":"137","author":"S Savonitto","year":"2018","journal-title":"Circulation"},{"issue":"41","key":"ref25","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"T Cuisset","year":"2017","journal-title":"Eur Heart J"},{"issue":"18","key":"ref26","doi-asserted-by":"crossref","first-page":"e012530","DOI":"10.1161\/JAHA.119.012530","article-title":"Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with ST-segment-elevation myocardial infarctions","volume":"8","author":"J Schmucker","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"H C Gwon","year":"2012","journal-title":"Circulation"},{"issue":"02","key":"ref28","first-page":"e003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Y Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"J Y Hahn","year":"2018","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"P Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"ref31","doi-asserted-by":"crossref","first-page":"e015560","DOI":"10.1161\/JAHA.119.015560","article-title":"Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the GLOBAL LEADERS trial","volume":"10","author":"P Vranckx","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"G De Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"21","key":"ref33","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"R Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"ref34","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"J Y Hahn","year":"2019","journal-title":"JAMA"},{"issue":"24","key":"ref35","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"H Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"23","key":"ref37","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"B K Kim","year":"2020","journal-title":"JAMA"},{"issue":"18","key":"ref38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"M Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"issue":"04","key":"ref39","first-page":"e009495","article-title":"Ticagrelor with or without aspirin in chinese patients undergoing percutaneous coronary intervention: a TWILIGHT China substudy","volume":"15","author":"Y Han","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"C Laudani","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacc.2021.06.012","article-title":"De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes","volume":"78","author":"S Shoji","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"ref42","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.108.790048","article-title":"Cardiovascular disease and risk factors in Asia: a selected review","volume":"118","author":"H Ueshima","year":"2008","journal-title":"Circulation"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.amjcard.2004.01.067","article-title":"C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study)","volume":"93","author":"M A Albert","year":"2004","journal-title":"Am J Cardiol"},{"issue":"06","key":"ref44","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1373\/clinchem.2007.098996","article-title":"Ethnic differences in C-reactive protein concentrations","volume":"54","author":"A Kelley-Hedgepeth","year":"2008","journal-title":"Clin Chem"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4070\/kcj.2020.0537","article-title":"Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences","volume":"51","author":"H K Kim","year":"2021","journal-title":"Korean Circ J"},{"issue":"12","key":"ref46","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1111\/j.1538-7836.2006.02237.x","article-title":"Plasma hemostatic factors and endothelial markers in four racial\/ethnic groups: the MESA study","volume":"4","author":"P L Lutsey","year":"2006","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-57030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T23:06:09Z","timestamp":1690326369000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-57030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":46,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2023,7,24]]},"published-print":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-57030","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]}}}